Umnl Vs LMNL
Umnl Vs LMNL
Umnl Vs LMNL
UMNL LMNL
Muscle power Paralysis or weakness below the level of the lesion. Paralysis or weakness at the level of the lesion.
Muscle No wasting, & if present it is late and due to disuse Early & marked wasting due to loss of muscle tone.
wasting atrophy.
Muscle tone Hypertonia (spasticity) below the level of the lesion. Hypotonia (flaccidity) at the level of the lesion.
Deep reflexes Hyperreflexia below the level. Hyporeflexia at the level.
Pathological May be present. Absent.
deep reflexes
Clonus May be present. Absent.
Superficial Lost if the lesion is above the segmental supply of Lost if the lesion involves the supply of the reflex.
reflexes the reflex.
Babinski Positive, i.e. dorsiflexion of the big toe ± fanning of Plantar flex ion of the toes, or no response.
the other toes.
Fasciculations Absent May be present in irritative lesion of the AHCs.
STROKE
ETIOLOGY: Ischemic 85% (Thrombosis [Most commonly athero], Embolism ), Hge 15%
RISK FACTORS: Non- modifiable [old, ♂, Type A, FH], Modifiable [esp. HTN]
CP: HEMIPLEGIA, HEMIANESTHESIA, Speech problems, Vision problems, Ataxia,
Cranial nerve paralysis.
CLINICAL TYPES: Stroke in evolution, Completed stroke
INVESTIGATIONS: CT, MRI, Cardiac & vascular imaging, CBC, PT, APTT, For RF
TREATMENT:
General care (Skin, Swallowing & nutrition, Balance of fluids, Breathing, Bladder,
Bowels)
Sx (↓ brain edema, Prophylaxis against STRESS ULCER, PHYSIOTHERAPY)
Specific:
I. Ischemic Stroke
1. Fibrinolytic therapy, tPA 3 to 4.5h,
2. Endovascular therapy [Stent retriever system, Penumbra system, MERCI])
3. Control of blood pressure
4. Antiplatelets: LDA, Clapidagrel, Ticlopidine, Dipyridamole
5. Anticoagulants . 6. Treatment of the cause.
II. Hemorrhagic stroke
1. Control of blood pressure. 2. Inracranial Pressure Control
3. Antifibrinolytic drugs 4. Surgery
TIAs
HEMIPLEGIA